| CAS NO: | 2156-56-1 |
| 包装 | 价格(元) |
| 10g | 电议 |
| 50g | 电议 |
| Physical Appearance | A solid |
| Storage | Desiccate at RT |
| M.Wt | 150.92 |
| Cas No. | 2156-56-1 |
| Formula | C2HCl2NaO2 |
| Solubility | ≥15.1 mg/mL in DMSO with gentle warming; ≥46.3 mg/mL in EtOH; ≥62.7 mg/mL in H2O |
| Chemical Name | sodium 2,2-dichloroacetate |
| Canonical SMILES | ClC(C([O-])=O)Cl.[Na+] |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Sodium dichloroacetate (DCA) is a specific inhibitor of pyruvate dehydrogenase kinase (PDK), with IC50 values of 183 μM and 80 μM for PDK2 and PDK4, respectively. DCA can inhibit the mitochondrial potassium channel axis, cause cancer cell apoptosis and inhibit tumor growth[1].
After DCA treatment, ROS levels in cancer cells increased, MMP depolarization, which can increase apoptosis both in vivo and in vitro[2].
In C57BL/6 mice, in vivo administration of DCA induced a 20% increase in survival and reduced tumor diameter, volume, and weight without affecting its weight and avoiding metastasis[3].
References：
[1]. Structure-guided Development of Specific Pyruvate Dehydrogenase Kinase Inhibitors Targeting the ATP-binding Pocket. Journal of Biological Chemistry, 2014, 289(7): 4432-4443.
[2]. Sun R C, Board P G, Blackburn A C. Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells. Molecular Cancer, 2011, 10(1): 142.
[3]. Franco-Molina M A, Mendoza-Gamboa E, Sierra-Rivera C A, et al. In vitro and in vivo antitumoral activitiy of sodium dichloroacetate (DCA-Na) against murine melanoma. African journal of microbiology research, 2012, 6(22): 4782-4796.
m.cnreagent.com